 Home > Active Ingredient News >

Blood System

Brukinsa, a BTK inhibitor in Baiji Shenzhou, is under review in Europe for the treatment of Fahrenheit polycyloproteinemia

 Time of Update: 2020-07-12

fda approved epoxy 1 cell phone key chinese 1 4 dibromobenzene cell gene therapy

Brukinsa (zanubrutinib, Zebtinib), a BTK small molecule inhibitor developed by Baiji Shenzhou, has been censored by European regulators to treat patients with Fahrenheit polycyteproteinemia (WM)
Blood: In multiple myeloma, monoclonal immunoglobulin promotes bone loss

 Time of Update: 2020-07-12

polyglutamic acid serum neural precursor cells stem cells used ph 1 acid model behavior

Most patients with multiple myeloma develop severe bone-soluble diseases Myeloma cells secrete immune globulin, the presence of monoclonal immunoglobulin in the serum of patients is important dia
59-year-old patient without cancer markers for more than 3 years after receiving CAR-T cell immunotherapy

 Time of Update: 2020-06-25

he detergent pods cell malignancies cell suspension culture fda medical device labeling seds medical

Even after three years, Andrew Parker and his oncologist, Michael Bishop, m.D., at the University of Chicago Medical Center, are in awe of the amazing turn of CAR-T cell immunotherapy 2016, Parker
Gene therapy LentiGlobin Treatment of Sickle Cell Disease: Phase I / Phase II Clinical Positive Results

 Time of Update: 2020-06-25

huntington's disease treatment year bluebird bio sickle cell malaria cell culture company

The latest data from Bluebird Bio's ongoing phase I/II study of gene therapy LentiGlobin for the treatment of sickle cell disease (SCD) shows that severe vascular aocstatory crisis (VOC) and acute
FDA Awards FT-4202 Orphan Drug for Sickle Cell Disease

 Time of Update: 2020-06-25

aristada fda approval which organ produces cholesterol vascular proliferation used cell disease

FORMA, a clinically phased biopharmaceutical company focused on rare haematology diseases and cancers, recently announced that the FDA has awarded its FT-4202 orphan drug designation, which is curre
Concerned about the rare disease "Red Blood Cell-producing Prosofe and X-Chain Dystrophy": Launched Global Phase III Clinical Trials of MT-7117

 Time of Update: 2020-06-25

hemoglobin blood test primary cell liver glucose production blood cell size red blood cells oxygen

Mitsubishi Tianbian Pharmaceutical Co., Ltd announced today that it has begun a global Phase III clinical trial of MT-7117, a selective black skin quality 1 receptor (MC1R) agonisant, aimed at treat
Baiji Shenzhou announced that combination chemotherapy was used in non-squamous non-small cell lung cancer patients, the stage 3 trial reached the main end point of progression-free survival

 Time of Update: 2020-06-25

brain cancer survival blood blood free uses monoclonal antibodies small fuel cell new drug approvals

Baiji Shenzhou announced that its anti-PD-1 monoanti-relizumab combined permeitus and platinum chemotherapy, a phase 3 trial for first-line treatment of non-squamous non-small cell lung cancer (NSCL
PKR activator mitapivat treatment of thalassemia: continued improvement in patient hemoglobin levels

 Time of Update: 2020-06-25

bone diseases symptoms 100 mg trazodone 1 6 symbol low dose ibuprofen namenda 10 mg

Agios Pharmaceuticals recently reported on Phase II studies showing that its experimental oral drug mitapivat (PKR activator) significantly improved hemoglobin (Hb) levels and the associated markers
Collection: Collection of Blood Research Highlights, April 16, 2020

 Time of Update: 2020-06-25

high viscosity oil hormone type 1 copper based blood 2 3 butanediol main source protein

The volume of high-start total metabolic tumors helps identify ultra-high-risk DLBCL populations https://doi.org/10.1182/blood.2019003526 https://doi.org/10.1182/blood.2019003526 early identif
Blood: The best drug for isosome platelet hyperplasia, aspirin optimizes antiplatelet therapy

 Time of Update: 2020-06-25

estazolam 2 mg 1 4 liter ritalin 40 mg 1 3 bisphosphoglycerate what 2 4

Ispeciallyanocal hyperplasia (ET) is characterized by abnormal macrocytocell production and an increased risk of blood clots Recommended antithrombotic treatment options: small dose aspirin, once da
A selection of Lancet research highlights on April 18, 2020

 Time of Update: 2020-06-25

mg 3 1000 mg aspirin dolac 10 mg phenylephrine 20 mg fentanyl 25 mg

1 Gixithabin-Platinum Chemotherapy for the late-stage epithelial skin cancer DOI: https://doi.org/10.1016/S0146/S0146-6736 (20)30415-3 is rare and pre-conditioned than bladder ontheuliopath
Blood: Vascular autonomic nerve function abnormalities in sickle cell disease (SCD)

 Time of Update: 2020-06-25

helium recovery system sickle cell curable blood vessel wall cold hot cpt2 disease symptoms

Subjects of sickle cell disease (SCD) exhibited subjective hypersensitivity to cold and hot sensations in the experimental environment, such as cold exposure and other known causes that cause the p
NMPA approves anti-PD-1 monoanti-relylibeads in Baiji Shenzhou for the treatment of locallate or metastatic urethral skin cancer

 Time of Update: 2020-06-25

anti ro antibody review 2 pd 1 pd l1 pathway platinum drugs pd 1 immunotherapy

Baiji Shenzhou announced that its anti-PD-1 antibody tislelizumab (tislelizumab) has been approved by the State Drug Administration of China (NMPA) for pD-L1 high expression, during or after platinu
Lancet: Acalabrutinib's first-line treatment of chronic lymphocytic leukemia is effective

 Time of Update: 2020-06-25

15 6 simplified 3 pi 4 ps 12 3 immunotherapy rho kinase inhibitor

Acalabrutinib is an alternative Bruton tyrosine kinase inhibitor that has the activity to treat chronic lymphocytic leukemia The researchers looked at the efficacy of Acalabrutinib in the treatment
Blood: miR-185/PAK6 axis regulates the survival of CML drug-resistant leukemia stem cells, predicting therapeutic reactive

 Time of Update: 2020-06-24

stem cell differentiation protein tyrosine kinase stem cells wiki cancer cell metastasis lice treatment target

Overcoming drug resistance and targeting cancer stem cells remains a challenge in cancer treatment To study the role of miRNAs in regulating drug resistance and the fate of leukemia stem cells (LSCs
Sudden reduction of white blood cells

 Time of Update: 2020-06-24

what residence time white blood cell slide cell number what cf number atp 4 11

On May 1, 84-year-old Grandmother Chen, who was picked up by 120 first aid, was admitted to hospital after not eating for two days of persistent low fever Body: Body temperature 37.8 degrees of the doctor immediately requested blood check routine , the results show that the WBC: 11.87 x 10 ?
Astellas announces its FLT3 inhibitor XOSPATA for leukemia and is under regulatory review at NMPA

 Time of Update: 2020-06-24

sildenafil drug class receptor tyrosine kinase dramamine drug tyrosine kinase inhibitors fail drug test

Astellas Pharmaceuticals (Astellas) has announced that XOSPATA (gilteritinib) new drug application (NDA) for the treatment of adult patients with acute myeloid leukemia (AML) with FLT3 mutation, rec
THE CAR-T opponent is here! CD19 monoanti-tafasitamab jointly come to nadoamine treatment lymphoma to submit FDA listing application

 Time of Update: 2020-06-24

ovarian cancer images model 5 3 importance stem cells fuel stabilizer car pancreatic cancer images

German biopharmaceutical company MorphoSys recently released the final analysis results of the new humanized Fc domain optimization immunobolaic-enhanced monoclonal antibody tafasitamab (MOR208) Pha
Blood: Predicting prognosis for abnormal hematopoietic function in patients with new myeloma

 Time of Update: 2020-06-24

high gene vitamin toxicity treatment munchausen syndrome cases 11 64 mm blood cell size

Center point: about 1/10 of myeloma patients showed MDS-related phenotype abnormalities at diagnosis and had poor survival MDS-related phenotype abnormalities alter the tumor microenvironment and
Blood: Antibodies that inhibit platelet phagocytosis, or treat ITP

 Time of Update: 2020-06-24

aquaporin 4 antibodies flow cytometry antibodies blood type test different types antibodies gad antibody test

Multi-clone anti-D is a first-line therapy for immune platelet reduction (ITP) Monoclonal antibodies are ideal alternatives, but although they have the ability to regulate red blood cells and cause

Go to Page

Blood System

Brukinsa, a BTK inhibitor in Baiji Shenzhou, is under review in Europe for the treatment of Fahrenheit polycyloproteinemia

Blood: In multiple myeloma, monoclonal immunoglobulin promotes bone loss

59-year-old patient without cancer markers for more than 3 years after receiving CAR-T cell immunotherapy

Gene therapy LentiGlobin Treatment of Sickle Cell Disease: Phase I / Phase II Clinical Positive Results

FDA Awards FT-4202 Orphan Drug for Sickle Cell Disease

Concerned about the rare disease "Red Blood Cell-producing Prosofe and X-Chain Dystrophy": Launched Global Phase III Clinical Trials of MT-7117

Baiji Shenzhou announced that combination chemotherapy was used in non-squamous non-small cell lung cancer patients, the stage 3 trial reached the main end point of progression-free survival

PKR activator mitapivat treatment of thalassemia: continued improvement in patient hemoglobin levels

Collection: Collection of Blood Research Highlights, April 16, 2020

Blood: The best drug for isosome platelet hyperplasia, aspirin optimizes antiplatelet therapy

A selection of Lancet research highlights on April 18, 2020

Blood: Vascular autonomic nerve function abnormalities in sickle cell disease (SCD)

NMPA approves anti-PD-1 monoanti-relylibeads in Baiji Shenzhou for the treatment of locallate or metastatic urethral skin cancer

Lancet: Acalabrutinib's first-line treatment of chronic lymphocytic leukemia is effective

Blood: miR-185/PAK6 axis regulates the survival of CML drug-resistant leukemia stem cells, predicting therapeutic reactive

Sudden reduction of white blood cells

Astellas announces its FLT3 inhibitor XOSPATA for leukemia and is under regulatory review at NMPA

THE CAR-T opponent is here! CD19 monoanti-tafasitamab jointly come to nadoamine treatment lymphoma to submit FDA listing application

Blood: Predicting prognosis for abnormal hematopoietic function in patients with new myeloma

Blood: Antibodies that inhibit platelet phagocytosis, or treat ITP